title: Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection.
abstract: It is unclear whether heart donors positive for hepatitis B core antibodies (anti-HBc) can transfer hepatitis B virus (HBV) infection to immunosuppressed heart recipients, or whether passive transfer of anti-HBc simulates a hepatitis B infection. Therefore, we performed a case-controlled study in 46 heart recipients who all tested negative for hepatitis B antigen (HbsAg), antiHBc, and hepatitis B surface antibodies before heart transplantation. Twenty-three patients (group 1) received hearts from anti-HBc-positive donors, while 23 other patients (group 2) received hearts from anti-HBc-negative donors. After heart transplantation, anti-HBc were present in 65.0% of blood samples among group 1 and 47.8% of the blood samples among group 2 (P > .05). HbsAg was undetectable in blood samples of all patients of both study groups. The immunoglobulin preparation that we regularly use for immune suppression immediately after heart transplantation contained a relatively high concentration of anti-Hbc antibodies. The nearly identical presence of anti-HBc in both study groups indicated that passive transfer via immunoglobulin preparations rather than HBV infection is the cause for the anti-HBc detected in heart recipients. Since only a small volume of blood is transferred with the donor heart, it seems to be rather unlikely that the donor heart might be the source of anti-HBc. In summary, we observed no evidence for HBV infection in those heart recipients who received organs from anti-HBc-positive donors. Moreover, our data demonstrated that the presence of anti-HBc in heart recipients frequently occurs but does not necessarily indicate a preceding HBV infection.
authors.affiliation: Klinik für Thorax und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Tenderich
authors.forename: A
authors.initials: A
authors.lastname: Zittermann
authors.forename: W
authors.initials: W
authors.lastname: Prohaska
authors.forename: S
authors.initials: S
authors.lastname: Wlost
authors.forename: U
authors.initials: U
authors.lastname: Fuchs
authors.forename: D
authors.initials: D
authors.lastname: Gürsoy
authors.forename: K
authors.initials: K
authors.lastname: Minami
authors.forename: R
authors.initials: R
authors.lastname: Koerfer
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D016022:Case-Control Studies; D003327:Coronary Disease / Q000601:surgery; D003404:Creatinine / Q000097:blood; D005260:Female; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D006509:Hepatitis B / Q000097:blood / Q000175:diagnosis* / Q000635:transmission; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000914:Antibodies, Viral; D006512:Hepatitis B Core Antigens; D003404:Creatinine